NO20090910L - Sulfonamid-derivater som adrenerge agonister og muskariniske antagonister - Google Patents

Sulfonamid-derivater som adrenerge agonister og muskariniske antagonister

Info

Publication number
NO20090910L
NO20090910L NO20090910A NO20090910A NO20090910L NO 20090910 L NO20090910 L NO 20090910L NO 20090910 A NO20090910 A NO 20090910A NO 20090910 A NO20090910 A NO 20090910A NO 20090910 L NO20090910 L NO 20090910L
Authority
NO
Norway
Prior art keywords
adrenergic agonists
sulfonamide derivatives
muscarinic antagonists
disorders
compounds
Prior art date
Application number
NO20090910A
Other languages
English (en)
Inventor
Graham Lunn
David Anthony Price
Lyn Howard Jones
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of NO20090910L publication Critical patent/NO20090910L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Det beskrives forbindelser av formel (1) og framgangsmåter for å fremstille disse, samt mellomprodukter anvendt i fremstilling derav, sammensetninger inneholdende 5 disse og anvendelser derav. Forbindelsene ifølge oppfinnelsen er nyttige innen flere sykdommer, forstyrrelser og tilstander, spesielt innen inflammatoriske, allergiske og respirasjonssykdommer, - forstyrrelser og tilstander.
NO20090910A 2006-10-04 2009-02-26 Sulfonamid-derivater som adrenerge agonister og muskariniske antagonister NO20090910L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82809906P 2006-10-04 2006-10-04
PCT/IB2007/002896 WO2008041095A1 (en) 2006-10-04 2007-09-21 Sulfonamide derivatives as adrenergic agonists and muscarinic antagonists

Publications (1)

Publication Number Publication Date
NO20090910L true NO20090910L (no) 2009-03-24

Family

ID=38947725

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090910A NO20090910L (no) 2006-10-04 2009-02-26 Sulfonamid-derivater som adrenerge agonister og muskariniske antagonister

Country Status (25)

Country Link
US (1) US20080090873A1 (no)
EP (1) EP2074094A1 (no)
JP (1) JP2010505810A (no)
KR (1) KR20090050104A (no)
CN (1) CN101522622A (no)
AP (1) AP2009004791A0 (no)
AR (1) AR063118A1 (no)
AU (1) AU2007303909A1 (no)
BR (1) BRPI0719270A2 (no)
CA (1) CA2665385A1 (no)
CL (1) CL2007002791A1 (no)
CO (1) CO6180437A2 (no)
CR (1) CR10700A (no)
EA (1) EA200900337A1 (no)
IL (1) IL197244A0 (no)
MA (1) MA30778B1 (no)
MX (1) MX2009002209A (no)
NO (1) NO20090910L (no)
PE (1) PE20080831A1 (no)
RS (1) RS20090137A (no)
TN (1) TN2009000112A1 (no)
TW (1) TW200823185A (no)
UY (1) UY30617A1 (no)
WO (1) WO2008041095A1 (no)
ZA (1) ZA200901320B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
US9518050B2 (en) 2012-12-18 2016-12-13 Almirall, S.A. Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
CN106336406B (zh) * 2015-07-10 2020-01-03 四川海思科制药有限公司 具有β2受体激动及M受体拮抗活性的八氢并环戊二烯衍生物及其在医药上的用途
EP3556435B1 (en) 2016-12-14 2020-10-28 Beijing Showby Pharmaceutical Co., Ltd. Class of bifunctional compounds with quaternary ammonium salt structure
NZ762856A (en) 2017-10-05 2020-07-31 Fulcrum Therapeutics Inc P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
JP2021505569A (ja) * 2017-12-04 2021-02-18 フリードリヒ−アレクサンダー−ウニヴェルシテート エアランゲン−ニュルンベルク Ｍ２よりもｍ３に対して選択性を有するフルオロフェニル置換ムスカリン受容体リガンド
AU2021296221A1 (en) 2020-06-26 2023-02-02 Mylan Pharma Uk Limited Formulations including 5-(3-(3-hydroxyphenoxy)azetidin-1-yl)-5-methyl-2,2-diphenylhexanamide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1615881A2 (en) * 2003-04-01 2006-01-18 Theravance, Inc. Diarylmethyl and related compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7358244B2 (en) * 2003-05-28 2008-04-15 Theravance, Inc. Azabicycloalkane compounds
DE602005001929T2 (de) * 2004-01-22 2007-12-06 Pfizer Inc. Sulfonamidderivate zur behandlung von krankheiten
US7320990B2 (en) * 2004-02-13 2008-01-22 Theravance, Inc. Crystalline form of a biphenyl compound
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound

Also Published As

Publication number Publication date
MA30778B1 (fr) 2009-10-01
CN101522622A (zh) 2009-09-02
WO2008041095A1 (en) 2008-04-10
US20080090873A1 (en) 2008-04-17
TN2009000112A1 (fr) 2010-08-19
JP2010505810A (ja) 2010-02-25
RS20090137A (sr) 2010-06-30
EA200900337A1 (ru) 2009-10-30
AU2007303909A1 (en) 2008-04-10
BRPI0719270A2 (pt) 2014-03-11
IL197244A0 (en) 2009-12-24
AR063118A1 (es) 2008-12-30
CL2007002791A1 (es) 2008-04-11
PE20080831A1 (es) 2008-06-20
KR20090050104A (ko) 2009-05-19
EP2074094A1 (en) 2009-07-01
CR10700A (es) 2009-04-24
AP2009004791A0 (en) 2009-04-30
CO6180437A2 (es) 2010-07-19
TW200823185A (en) 2008-06-01
MX2009002209A (es) 2009-03-16
CA2665385A1 (en) 2008-04-10
ZA200901320B (en) 2010-04-28
UY30617A1 (es) 2008-05-31

Similar Documents

Publication Publication Date Title
NO20090910L (no) Sulfonamid-derivater som adrenerge agonister og muskariniske antagonister
NO20084005L (no) Aminderivater
ATE463495T1 (de) Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
NO20070526L (no) Kinazolindionderivater som parp-inhibitorer
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
MXPA05012840A (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades.
GEP20125437B (en) New sulfonamide derivatives as bradykinin antagonists
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
MY139690A (en) Sulfonamide derivatives for the treatment of diseases.
NO20076515L (no) Hydantoinforbindelser
NO20062983L (no) Sulfonamid-derivater for behandling av sykdommer
ATE537170T1 (de) Cgrp-rezeptorantagonisten
NO20084363L (no) 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
NO20091052L (no) Diaryleterderivater og anvendelser derav
NO20051503L (no) Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
WO2008074803A8 (en) 4-benzyl-l ( 2h) -phthalazinones as h1 receptor antagonists
EA200601462A1 (ru) Соединения для лечения заболеваний
WO2007073303A3 (en) Novel benzimidazole derivatives as vanilloid receptor 1 (vrl) inhibitors
DE602007004327D1 (de) Einen azepin-kern enthaltende antagonisten des histaminrezeptors
NO20081587L (no) Aerosolformulering for inhalering
NO20080839L (no) Isotopsubstituerte protonpumpeinhibitorer
WO2006078554A3 (en) Cgrp receptor antagonists
DE602007005387D1 (de) Ptors
EA200601510A1 (ru) Производные фенилэтаноламина в качестве бета-2-агонистов

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application